Customize your JAMA Network experience by selecting one or more topics from the list below.
Treatment with the HIV combination drug lopinavir-ritonavir did not accelerate recovery or improve mortality rates among hospitalized patients with severe coronavirus disease 2019 (COVID-19), a trial in the New England Journal of Medicine reported.
An HIV medication was no better than standard care for patients with severe coronavirus disease 2019.
The study’s 199 patients with confirmed severe acute respiratory syndrome coronavirus 2 infection were randomly assigned to receive standard care plus 400 mg of lopinavir and 100 mg of ritonavir twice a day for 14 days or standard care alone.
For both groups the time to clinical improvement—the primary end point—was a median of 16 days. Researchers stopped the intervention early for 13 patients who experienced mainly gastrointestinal adverse events.
Slomski A. No Benefit for Lopinavir–Ritonavir in Severe COVID-19. JAMA. 2020;323(20):1999. doi:10.1001/jama.2020.6793
Coronavirus Resource Center
Create a personal account or sign in to: